These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 26271624

  • 1. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
    Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y.
    BMC Gastroenterol; 2015 Aug 14; 15():103. PubMed ID: 26271624
    [Abstract] [Full Text] [Related]

  • 2. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T.
    J Gastroenterol; 2016 Mar 14; 51(3):241-51. PubMed ID: 26162647
    [Abstract] [Full Text] [Related]

  • 3. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.
    Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR.
    J Crohns Colitis; 2018 Feb 28; 12(3):289-297. PubMed ID: 29121178
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A, Allegretta L, Chiri S, Della Valle N, Elisei W, Forti G, Lorenzetti R, Mocci G, Penna A, Pranzo G, Ricciardelli C, Picchio M.
    Minerva Gastroenterol Dietol; 2017 Dec 28; 63(4):313-318. PubMed ID: 28293938
    [Abstract] [Full Text] [Related]

  • 5. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D, Hall B, Jeyarajah SK, Smith S, Breslin N, Ryan B, McNamara D.
    Inflamm Bowel Dis; 2017 Jul 28; 23(7):1154-1159. PubMed ID: 28486256
    [Abstract] [Full Text] [Related]

  • 6. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
    Singh N, Rosenthal CJ, Melmed GY, Mirocha J, Farrior S, Callejas S, Tripuraneni B, Rabizadeh S, Dubinsky MC.
    Inflamm Bowel Dis; 2014 Oct 28; 20(10):1708-13. PubMed ID: 25153505
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME, Werida RH, Radwan MA, Askar SR, Omran GA, El-Mohamdy MA, Hagag RS.
    Inflammopharmacology; 2024 Oct 28; 32(5):3259-3269. PubMed ID: 38985232
    [Abstract] [Full Text] [Related]

  • 8. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.
    J Pediatr Gastroenterol Nutr; 2018 Oct 28; 67(4):507-512. PubMed ID: 29901557
    [Abstract] [Full Text] [Related]

  • 9. Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.
    Barberio B, D'Incà R, Facchin S, Dalla Gasperina M, Fohom Tagne CA, Cardin R, Ghisa M, Lorenzon G, Marinelli C, Savarino EV, Zingone F.
    Inflamm Bowel Dis; 2020 Apr 11; 26(5):756-763. PubMed ID: 31504536
    [Abstract] [Full Text] [Related]

  • 10. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
    Frin AC, Filippi J, Boschetti G, Flourie B, Drai J, Ferrari P, Hebuterne X, Nancey S.
    Dig Liver Dis; 2017 Jan 11; 49(1):11-16. PubMed ID: 27693318
    [Abstract] [Full Text] [Related]

  • 11. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
    Muñoz Villafranca C, Bravo Rodríguez MT, Ortiz de Zárate J, Arreba González P, García Kamiruaga I, Heras Martín JI, Cabezudo Gil P, Orive Cura V.
    Gastroenterol Hepatol; 2016 Jan 11; 39(7):442-8. PubMed ID: 26948837
    [Abstract] [Full Text] [Related]

  • 12. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L, Muñoz F, Barrio J, Muñoz C, Pajares R, Rivero M, Prieto V, Legido J, Bouhmidi A, Herranz M, Fernández N, Sánchez-Ocaña R, Joao D, Santos F.
    Scand J Gastroenterol; 2016 Jan 11; 51(2):186-95. PubMed ID: 26200929
    [Abstract] [Full Text] [Related]

  • 13. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S.
    J Crohns Colitis; 2016 Sep 11; 10(9):1015-23. PubMed ID: 27022161
    [Abstract] [Full Text] [Related]

  • 14. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
    Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Nardone OM, De Vitis I, Papa A, Rapaccini GL, Guidi L.
    Inflamm Bowel Dis; 2014 Aug 11; 20(8):1368-74. PubMed ID: 24983979
    [Abstract] [Full Text] [Related]

  • 15. CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis.
    Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, Martin ST, Buckley M, Sheridan J, Horgan G, Mulcahy HE, Cullen G, Doherty GA.
    J Clin Gastroenterol; 2018 Jul 11; 52(6):e48-e52. PubMed ID: 28737646
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X.
    Inflamm Bowel Dis; 2013 Nov 11; 19(12):2568-76. PubMed ID: 24013361
    [Abstract] [Full Text] [Related]

  • 17. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis.
    Sato S, Chiba T, Nakamura S, Matsumoto T.
    J Gastroenterol Hepatol; 2015 Oct 11; 30(10):1467-72. PubMed ID: 25968585
    [Abstract] [Full Text] [Related]

  • 18. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA, Ramadan HK, Ismael AA, Mohamed KF, El-Attar MM, Alhelali I.
    Saudi J Gastroenterol; 2017 Oct 11; 23(4):238-245. PubMed ID: 28721978
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H, Arai K, Kagimoto S, Kunisaki R, Hida N, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T.
    BMC Pediatr; 2019 Oct 13; 19(1):351. PubMed ID: 31607268
    [Abstract] [Full Text] [Related]

  • 20. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S.
    J Crohns Colitis; 2015 Jul 13; 9(7):525-31. PubMed ID: 25895875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.